Publications by authors named "T Fehm"
The progress that has been made in recent years in relation to liquid biopsies in general and circulating tumor DNA (ctDNA) in particular can be seen as groundbreaking for the future of breast cancer treatment, monitoring and early detection. Cell-free DNA (cfDNA) consists of circulating DNA fragments released by various cell types into the bloodstream. A portion of this cfDNA, known as ctDNA, originates from malignant cells and carries specific genetic mutations.
View Article and Find Full Text PDFIntroduction: Minimally invasive surgery is increasing in all fields of surgery. It is currently unknown whether structured training is superior to self-directed training. The aim of this study is to analyze the enhancement of surgical skills in laparoscopy box trainers in a systematically guided training program compared to self-directed training.
View Article and Find Full Text PDFArticle Synopsis
- The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a system for monitoring women at high risk for breast cancer, recommending annual screenings using the BOADICEA risk model for those with a 10-year risk of 5% or more.
- Women with a family history of breast cancer may qualify for increased surveillance as they age, even if their initial risk doesn’t meet the threshold.
- Two methods were compared for determining when a woman's risk increases: the 'prediction by aging pedigree' (AP) which tracks family history over time, and a simpler 'conditional probability' (CP) approach, which estimates future risks based on initial assessments; the CP method was found to be
Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059), evaluating the combination of durvalumab with chemotherapy, for longitudinal alterations of gene expression. Durvalumab induces an activation of immune and stromal gene expression as well as a reduction of proliferation-related gene expression.
View Article and Find Full Text PDFBackground: The COVID-19 pandemic has transformed breast cancer care for patients and healthcare providers. Circumstances varied greatly by region and hospital, depending on COVID-19 prevalence, case mix, hospital type, and available resources. These challenges have disrupted screening programs and have been particularly distressing for both women with a breast cancer diagnosis and their providers.
View Article and Find Full Text PDF